Part of the reluctance to reimburse for telemedicine is that policy makers aren’t aware of the wide range of evidence that currently exists and supports increasing reimbursement for telemedicine, said Kristen McGovern, JD, partner at Sirona Strategies.
Part of the reluctance to reimburse for telemedicine is that policy makers aren’t aware of the wide range of evidence that currently exists and supports increasing reimbursement for telemedicine, said Kristen McGovern, JD, partner at Sirona Strategies.
Transcript (slightly modified)
What has been the reluctance to increase reimbursement for telemedicine?
Telemedicine, I think, in the minds of policy makers has really traditionally been a rural issue. When it made its way into the Medicare reimbursement regulations, it was really to increase access to care in rural areas. Over the past few years, obviously technology has far advanced and now all Americans, a lot of people carry around smartphones or have computers, and they have the ability to access care in different ways. And so it’s no longer a rural issue. It’s really an issue for everyone.
I think the reluctance around reimbursement has been primarily around, you know in the Medicare space there’s a lot of questions about whether seniors, how technology proficient they are and whether they would be able to actually use the technology. There’s also questions about utilization and whether we’re going to blow the budget by giving patients this easy, convenient access to care. And then there’s also questions about research. Policy makers like to have a wide body of evidence before they make any decisions and we do believe that we have a significant body of research. So, it’s just educating people about the telemedicine work that’s already been done and that there is a body of evidence out there that can support increased reimbursement.
Do you believe the idea that senior citizens do not understand how to use telemedicine is an outdated concern?
We are seeing that seniors are much more tech-savvy and if they aren’t, then a lot of times they have a caregiver who is. Generally, the caregiver is a child or someone in their family who’s a little bit younger who may be more experienced with technology and if they don’t know how to use it, can help them use it.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More